Evidence map›Paper›PMID 34528697›Full record

ReviewInternational journal of molecular medicine2021

CircRNA: A novel potential strategy to treat thyroid cancer (Review).

Guomao Zhu, Xingyu Chang, Yuchen Kang, Xinzhu Zhao, Xulei Tang, Chengxu Ma, Songbo Fu

Abstract readReview
In one paragraph

Review in International journal of molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Circular RNAs as Biomarkers in the Diagnosis of Human Diseases.Advances in experimental medicine and biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guomao Zhu *Endocrinology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Xingyu Chang *Endocrinology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Yuchen KangThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Xinzhu ZhaoEndocrinology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Xulei TangEndocrinology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Chengxu MaEndocrinology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Songbo FuEndocrinology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer (TC) is the most common type of endocrine cancer. Over the last 50 years, the global incidence of TC has been increasing. The survival rate of TC is higher than that of most other types of cancer, but it depends on numerous factors, including the specific type of TC and stage of the disease. Circular RNAs (circRNAs) are a new class of long noncoding RNA with a closed loop structure that have a critical role in the complex gene regulatory network that controls the emergence of TC. The most important function of circRNAs is their ability to specifically bind to microRNAs. In addition, the biological functions of circRNAs also include interactions with proteins, regulation of the transcription of genes and acting as translation templates. Based on the characteristics of circRNAs, they have been identified as potential biomarkers for the diagnosis of tumors. In the present review, the function and significance of circRNAs and their potential clinical implications for TC were summarized. Furthermore, possible treatment approaches involving the use of mesenchymal stem cells (MSCs) and exosomes derived from MSCs as carriers to load and transport circRNAs were discussed.

Indexed as

AnimalsBiomarkers, TumorExosomesGene Expression Regulation, NeoplasticHumansMesenchymal Stem CellsRNA, CircularThyroid NeoplasmsBiomarkers, TumorRNA, CircularcircRNAsexosomesmesenchymal stem cellsthyroid cancer

Identifiers

PMID34528697
PMCPMC8480381

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.